Secret Disease Meeting Announced With Zero Details Given
Published Date: 1/7/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding a private meeting from January 27-29, 2025, to review secret contract proposals for new tests to detect Mycoplasma genitalium infections. This affects researchers and companies competing for funding to develop these diagnostics. The meeting keeps sensitive info safe and helps decide who gets money to fight infections.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Closed review to protect trade secrets
The meeting is closed to the public under 5 U.S.C. sections 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, patentable commercial material, and personal information. This preserves privacy and proprietary details for companies and researchers whose contract proposals are discussed.
Proposals reviewed for Mycoplasma genitalium diagnostics
The National Institute of Allergy and Infectious Diseases will review and evaluate contract proposals for 'Development of Diagnostics for Mycoplasma genitalium Infection (Topic 143)' on January 27-29, 2025, from 9:00 a.m. to 1:00 p.m. This affects researchers and companies that submitted proposals on that topic because their submissions will be evaluated at that meeting.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-20710, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Modify the Required Criteria To Qualify for the Reduced Incremental Fee
Investors Exchange (IEX) is changing the rules for who can get a discount on certain trading fees. Starting November 1, 2026, members will need to meet new criteria to qualify for the reduced incremental fee, which could save or cost them money depending on their trading activity. This change affects all IEX members and kicks in right away to keep things fair and clear.
2026-20729, Proposed Agency Information Collection Activities; Comment Request
The National Credit Union Administration (NCUA) wants to update its Call Report form to include questions about credit unions’ activities with payment stablecoins. This change affects all credit unions and will start with reports due March 31, 2027. The NCUA is asking for public comments by December 8, 2026, to make sure the new form works well without causing extra costs or hassle.
2026-20702, Notice of Public Meetings of the Virginia Advisory Committee to the U.S. Commission on Civil Rights
The Virginia Advisory Committee to the U.S. Commission on Civil Rights is holding virtual public meetings to discuss how Virginia public universities are following rules about fair student admissions. Anyone interested can join these Zoom meetings on October 27, November 10, and December 15, 2026, to listen and share their thoughts. These meetings don’t cost money to attend, but phone users might pay regular call fees.
2026-20708, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Amend the IEX Equities Fee Schedule
IEX is shaking up its fee schedule starting November 1, 2026, by tweaking who gets rebates for adding displayed liquidity and changing rebate amounts. This affects IEX members who trade stocks, giving them new ways to save or earn more on fees. The changes kick in right away after filing, so traders should get ready to adjust their strategies and cash flow.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
2026-20779, Passenger Vehicle and Light Truck Tires From Thailand: Preliminary Results and Rescission, in Part, of Antidumping Duty Administrative Review; 2024-2025
The U.S. Department of Commerce found that tires from Thailand were sold in the U.S. for less than their normal price between July 2024 and June 2025. This means some importers might have to pay extra duties to keep things fair. The review process had some delays due to government shutdowns, but now the preliminary results are out and open for comments.
Previous / Next Documents
Previous: 2025-00105, National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on January 28, 2025, to review important grant applications for clinical trial projects. This meeting affects researchers seeking funding and keeps sensitive information private. The decisions made could impact future medical research funding and progress.
Next: 2025-00107, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in early 2025 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide which science projects get funding. Researchers applying for grants should note these dates as they impact which projects move forward with NIH support.